Not Yet RecruitingNot Applicable

Esketamine Combined With PRF of DRG for Acute/Subacute Zoster-associated Pain

China184 participantsStarted 2025-04-01

Plain-language summary

To assess the 1-month effects and safety of esketamine - PRF -standardized drug treatment against PRF -standardized drug treatment acute/subacute zoster-associated pain (ZAP) patients.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Ages more than 18 years;
✓. Patients with onset of herpes zoster (HZ) rash less than 90 days;
✓. HZ affected the spinal nerves (cervical/thoracic/lumbar nerve);
✓. Having an average pain score of at least 4 on a Numeric Rating Scale (NRS, 0 = no pain, 10= worst possible pain)；
✓. Planned to perform CT-guided PRF treatment of the dorsal root ganglion(DRG).

Exclusion criteria

✕. Obstructive sleep apnoea syndrome;
✕. Those who receive other more invasive treatments, such as radiofrequency thermocoagulation (RFT) of DRG.
✕. A history of systemic immune diseases, organ transplantation, or cancers;
✕. A history of severe cardiopulmonary, hepatic, renal dysfunction or coagulation function disorder;
✕. A history of schizophrenia, epilepsy, or myasthenia gravis, delirium;
✕. Comorbid hyperthyroidism or phaeochromocytoma;
✕. Recent history of drug abuse;
✕. Having contraindications to esketamine;

What they're measuring

the NRS score at 1 month after treatment.

Timeframe: 1-month period

Trial details

NCT IDNCT06914206

SponsorBeijing Tiantan Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-04-01

Contact for this trial

Fang Luo

+86 13611326978 13611326978@163.com

View on ClinicalTrials.gov More Herpes Zoster trials